Prior Authorization Approval Criteria

Supartz

Generic name: All derivatives of Hyaluronate (hyaluronan, hyaluronic acid, sodium hyaluronate, hylan polymers, cross-linked hyaluronate etc.)

Brand name: Euflexxa, Hyalgan, Gel-One, Orthovisc, Supartz, Synvisc, Synvisc-One

Medication class: Viscosupplements

FDA-approved uses: Intra-articular injections for treatment of mild to moderate osteoarthritis of knees.

Available dosage forms: injectable

Usual dose: One injection weekly (actual amount varies from product to product)

Approximate monthly cost: (based on AWP 2013)
- J7321 Supartz $212.00 per injection x3-5 inj = $636-1060.00
- J7321 Hyalgan $156.00 per injection x3-5 inj = $468-780.00
- J7323 Euflexxa $329.48 per injection x3 inj = $988.44
- J7322 Synvisc $379.26 per injection x3 inj = $1137.78
- J7322 Synvisc-One $1137.78 per injection x1 inj = $1137.78
- J7324 Orthovisc $372.78 per injection x3 inj = $1118.34
- J7324 Gel-One $1170.00 per injection x1 inj = $1170.00

Duration of therapy: One to five weeks, depending on the product

Criteria for use (bullet points below are all inclusive unless otherwise noted):
- If patient meets the criteria for viscosupplement therapy, FCHP will only approve the preferred formulary products (Euflexxa, Supartz, or Hyalgan). Orthovisc, Synvisc or Gel-One may be approved if the patient has tried and failed or was intolerant to the FCHP preferred products.
- Patient has clinically documented osteoarthritis of the knees
- Efficacy of intra-articular corticosteroid injection lasting less than 6-8 weeks

Criteria for continuation of therapy:
- There are no data on repeated courses of therapy for Euflexxa and Supartz; there is no evidence of increased adverse drug events in repeated courses of therapy for Hyalgan, Synvisc, and Orthovisc when separated by at least six months.

Caution:
- Remove any joint effusion present before injecting Viscosupplements
- Do not use concomitantly with quaternary ammonium compounds
- Do not inject with anesthetics or other medications
- Do not use in severely inflamed knees
- Use Hyalgan, Synvisc, Supartz and Orthovisc with caution in patients who are allergic to avian proteins, feathers, or eggs

The criteria listed above applies to Fallon Health Plan and its subsidiaries.
Monitoring:
- Advise patients of likely side effects (injection site reactions)

Contraindication:
- Do not use in patients with known hypersensitivity to hyaluronate derivatives
- Do not use in the presence of joint infections or skin diseases or infections in the area of the injection site

Not approved if:
- Patient does not meet the above stated criteria
- Being requested for joints other than knees
- Patient has any contraindications to the use of product

Fallon Health Pharmacy and Therapeutics Committee approval: __________________________

Date: __________________________

Adopted: 04/13/05
Rev: 03/14/07, 03/12/08